Unveiling the therapeutic potential of IHMT-337 in glioma treatment: targeting the EZH2-SLC12A5 axis
Authors:
Open Access
- 17 June 2024
- journal article
- research article
- Published by Springer Nature in Molecular Medicine
- Vol. 30 (1) , 1-19
Abstract
Glioma is the most common malignant tumor of the central nervous system, with EZH2 playing a crucial regulatory role. This study further explores the abnormal expression of EZH2 and its mechanisms in regulating glioma progression. Additionally, it was found that IHMT-337 can potentially be a therapeutic agent for glioma. The prognosis, expression, and localization of EZH2 were determined using bioinformatics, IHC staining, Western blot (WB) analysis, and immunofluorescence (IF) localization. The effects of EZH2 on cell function were assessed using CCK-8 assays, Transwell assays, and wound healing assays. Public databases and RT-qPCR were utilized to identify downstream targets. The mechanisms regulating these downstream targets were elucidated using MS-PCR and WB analysis. The efficacy of IHMT-337 was demonstrated through IC50 measurements, WB analysis, and RT-qPCR. The effects of IHMT-337 on glioma cells in vitro were evaluated using Transwell assays, EdU incorporation assays, and flow cytometry. The potential of IHMT-337 as a treatment for glioma was assessed using a blood–brain barrier (BBB) model and an orthotopic glioma model. Our research confirms significantly elevated EZH2 expression in gliomas, correlating with patient prognosis. EZH2 facilitates glioma proliferation, migration, and invasion alongside promoting SLC12A5 DNA methylation. By regulating SLC12A5 expression, EZH2 activates the WNK1-OSR1-NKCC1 pathway, enhancing its interaction with ERM to promote glioma migration. IHMT-337 targets EZH2 in vitro to inhibit WNK1 activation, thereby suppressing glioma cell migration. Additionally, it inhibits cell proliferation and arrests the cell cycle. IHMT-337 has the potential to cross the BBB and has successfully inhibited glioma progression in vivo. This study expands our understanding of the EZH2-SLC12A5 axis in gliomas, laying a new foundation for the clinical translation of IHMT-337 and offering new insights for precision glioma therapy.Keywords
Funding Information
- Research Funds of Centre for Leading Medicine and Advanced Technologies of IHM (2023IHM01041)
- Clinical Medical research transformation Project of Anhui Province (202204295107020020)
- the Joint Fund for Medical Artificial Intelligence (MAI2022Q011)
This publication has 63 references indexed in Scilit:
- Neocortical excitation/inhibition balance in information processing and social dysfunctionNature, 2011
- The Polycomb complex PRC2 and its mark in lifeNature, 2011
- EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-β-Catenin SignalingCancer Cell, 2011
- Instantaneous Modulation of Gamma Oscillation Frequency by Balancing Excitation with InhibitionNeuron, 2009
- Regulation of WNK1 by an Autoinhibitory Domain and AutophosphorylationJournal of Biological Chemistry, 2002
- Excitatory actions of gaba during development: the nature of the nurtureNature Reviews Neuroscience, 2002
- WNK kinases, a novel protein kinase subfamily in multi-cellular organismsOncogene, 2001
- Disruption of KCC2 Reveals an Essential Role of K-Cl Cotransport Already in Early Synaptic InhibitionNeuron, 2001
- The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disordersEuropean Journal of Human Genetics, 2000
- Localization and Developmental Expression Patterns of the Neuronal K–Cl Cotransporter (KCC2) in the Rat RetinaJournal of Neuroscience, 2000